Microstructured Transdermal Systems (MTS)


Kindeva’s MTS platform provides elegant microneedle-based delivery devices, refined and suited to our partners’ programs. Analytical & technical leadership: From early-phase feasibility to final design requirements, we can meet the needs of challenging drug formulations. • Feasibility and early-phase development capabilities • Human tolerability and human factors studies • Proven ability to develop challenging drug formulations • Preclinical and clinical capabilities • Regulatory leadership and expert data analysis to support submissions and filings Innovative devices: Refined over several device generations, Kindeva’s microstructured systems are designed for consistent intradermal delivery of vaccines and biologics. Our patient-friendly technology is available in two formats, providing an option of delivery routes to enable your commercial success. • Solid Microneedles – offers potential for increased immunogenicity, dose sparing, cold chain elimination, and increased patient convenience via self-administration • Hollow Microneedles – offers reproducible intradermal delivery of a wide range of viscosities Operational excellence: With sophisticated project management, rigorous quality processes, manufacturing excellence, and cGMP facilities, Kindeva supports a reliable supply chain for your program. • Automated Array Molding and Packaging • Aseptic Array Coating for Solid Microneedles • Qualified Equipment for Device Assembly Process • Manufacturing capability for Preclinical, Clinical, and Scale-up Activities